2024 Annual Meeting | Industry Therapeutic Update from Eisai: The Time is Now: Urgent Need for a Patient-Centered Care Framework in Alzheimer's

Date Tuesday 04/16/24

Time 06:00 PM - 08:00 PM MDT Add To Calendar

Location Embassy Suites | Silverton 1-3

Session Format This program will be presented in-person only

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type Industry Therapeutic Update

Director(s) Marwan N. Sabbagh, MD, FAAN, Julie B. Schwartzbard, MD, FAAN, Justin S. Moon, MD

Topic(s) General Neurology, Aging, Dementia, and Behavioral Neurology

Learning Objectives This session aims to humanize recent advances in Alzheimer’s Disease (AD) treatments through practical guidance for general neurologists to support optimal application of emerging AD treatments. Three practicing neurology experts will share useful insights to guide general neurologists through the implementation of monoclonal antibodies for AD within varied clinical practice settings. Topics in the presentation will include a discussion on the recent advances in AD care and the importance of early diagnosis, an overview of the pathophysiology of AD and how it contributes to disease progression, detailed differential diagnosis with a focus on advancements in diagnostic technologies, and an understanding of emerging AD treatments and how they will impact the patient care pathway. A multi-disciplinary panel will follow to provide practical recommendations for adapting collaborative care teams to overcome challenges that may occur with implementation of emerging AD treatments. This session will emphasize the importance of early AD diagnosis and treatment initiation, increase the understanding of AD fundamentals, demonstrate the role of emerging AD treatments and their impact on disease management, and provide actionable clinical guidance for collaborative care teams to provide a holistic approach to optimize patient care in AD.
This program is NOT accredited for continuing education by any organization. Additionally, Industry Therapeutic Updates program content and the views expressed herein are those of the presenting corporate entity and not of the AAN. These programs are not an official part of the 2024 AAN Annual Meeting education or scientific programs, nor are they endorsed by the AAN. The AAN cannot affirm claims pertaining to FDA off-label medication, research use of pre-FDA drugs, or other research information that might be discussed. Industry Therapeutic Updates are industry events.

CME Available No CME available

Program Materials Program Evaluations

Event Timeline
06:00 PM - 08:00 AM MDT	Speaker	Industry Therapeutic Update from Eisai: The Time is Now: Urgent Need for a Patient-Centered Care Framework in Alzheimer's

Faculty Disclosures
Marwan N. Sabbagh, MD, FAAN	Dr. Sabbagh has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Eisai. Dr. Sabbagh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genetech=Roche. Dr. Sabbagh has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Novo Nordisk. Dr. Sabbagh has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Lilly. Dr. Sabbagh has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Synaptogenix. Dr. Sabbagh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Signant Health. Dr. Sabbagh has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Anavex. Dr. Sabbagh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Prothena. Dr. Sabbagh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Cognito Therapeutics. Dr. Sabbagh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for GSK. Dr. Sabbagh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Abbvie. Dr. Sabbagh has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for CervoMed. Dr. Sabbagh has stock in Neurotau. Dr. Sabbagh has stock in Seq Biomarque. Dr. Sabbagh has stock in uMethod Health. Dr. Sabbagh has stock in Athira. Dr. Sabbagh has stock in Lighthouse Pharmaceuticals. Dr. Sabbagh has stock in Alzheon. The institution of Dr. Sabbagh has received research support from NIH. The institution of Dr. Sabbagh has received research support from ADDF.
Julie B. Schwartzbard, MD, FAAN	Dr. Schwartzbard has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lilly. Dr. Schwartzbard has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for NFL Concussion Settlement Program. Dr. Schwartzbard has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amneal. Dr. Schwartzbard has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Lilly. Dr. Schwartzbard has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Biohaven. Dr. Schwartzbard has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Abbvie. Dr. Schwartzbard has received personal compensation in the range of $100,000-$499,999 for serving as an Expert Witness for Several. Dr. Schwartzbard has received research support from Lilly. Dr. Schwartzbard has received research support from Eisai. Dr. Schwartzbard has received research support from TauRx. Dr. Schwartzbard has received research support from Sparc. Dr. Schwartzbard has received research support from Roche. Dr. Schwartzbard has received research support from Cerevel. Dr. Schwartzbard has received research support from Amneal. Dr. Schwartzbard has received research support from Neuroderm.
Justin S. Moon, MD	No disclosure on file